Earnings Routine +

Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Quebec

Cannara Biotech Confirms Profitability Amidst Revenue Growth Deceleration

By The Northwire Desk — AI Analysis Apr 14, 2026 · 07:00 LOVE · 2.05 Cannara Biotech Inc.

Executive Summary

Event: Cannara Biotech reported Q2 Fiscal 2026 financial results on April 14, 2026.
Revenue: Total net revenues of $27.2 million (up 2% YoY); Gross cannabis revenues of $37.8 million (up 3% YoY). This represents a significant slowdown compared to Q1 Fiscal 2026, which saw 20% YoY revenue growth.
Profitability: Net income of $1.7 million ($0.02 per share), down from $3.3 million in Q2 2025. Adjusted EBITDA was $6.0 million, down from $7.1 million YoY.
Cash Flow: Operating cash flow improved significantly to $2.9 million compared to -$2.6 million in the prior year period.
Market Share: Achieved #1 retail market share position in Quebec (14.3%) and increased national retail market share to 4.4%.
Capital: Completed a non-brokered private placement with Phoenician Capital LLC for $6.3 million (3,000,000 shares at $2.10/share), announced previously in February 2026.
Operations: Capital expenditures were $3.2 million, primarily for the Valleyfield Facility construction project.

Material Impact

Positive Aspects: The company has successfully transitioned to positive operating cash flow ($2.9M vs -$2.6M), which is a critical milestone for liquidity and reduces immediate dilution risk. Maintaining profitability (Net Income $1.7M) in a challenging cannabis market validates the business model. Market share gains in Quebec (#1 position) provide a defensive moat in their home province.
Negative Aspects: Revenue growth has decelerated sharply from 20% YoY in Q1 to just 2% YoY in Q2. Adjusted EBITDA declined year-over-year ($7.1M to $6.0M), suggesting margin pressure or increased operational costs relative to sales. The private placement price of $2.10 is close to the current trading price, indicating limited upside from this capital raise alone.
Conclusion: The news confirms execution on profitability and cash flow but signals a maturation phase where high growth rates are difficult to sustain. It does not materially alter the investment thesis established in FY25 and Q1 2026, hence it is Routine - Positive rather than Material - Positive.

LOVE · Price

Company Overview

Overview: Cannara Biotech is a vertically integrated cannabis company focused on premium consumer brands (Tribal, Nugz, Orchid CBD). They operate cultivation and processing facilities in Quebec.
Flagship Project: The Valleyfield Facility is the core growth driver. It includes a mega-production facility with 24 grow zones. Phase 1 completion was targeted for FY2026. Expansion plans include activating three additional grow zones for FY2027.
Development Status: As of Q2 2026, construction is progressing, and half of the 24-zone capacity was active in previous reports (Q1 2026).

More from Cannara Biotech Inc.